Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 7, 2012, Pages 849-856

  Kang, Se Hun ^a   Kim, Do Young ^a,b,c   Jeon, Soung Min ^a   Ahn, Sang Hoon ^a,b,c   Park, Jun Yong ^a,b,c   Kim, Seung Up ^a,b,c   Kim, Ja Kyung ^a,c   Lee, Kwan Sik ^a,c   Chon, Chae Yoon ^a,b   Han, Kwang Hyub ^a,b,c  

^a Yonsei University   (South Korea)

^b Yonsei Liver Cancer Special Clinic   (South Korea)

^c Liver Cirrhosis Clinical Research Center   (South Korea)

Author keywords

Fetoprotein; hepatocellular carcinoma; prothrombin induced by vitamin K absence or antagonist II; survival

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; SURVIVAL PREDICTION; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84862182834     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283535c34     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15:1301-1314.
3. Johnson PJ, Melia WM, Palmer MK, Portmann B, Williams R. Relationship between serum alpha-foetoprotein, cirrhosis and survival in hepatocellular carcinoma. Br J Cancer 1981; 44:502-505.
4. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77:2217-2222.
5. Shimada M, Takenaka K, Fujiwara Y, Gion T, Kajiyama K, Maeda T, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996; 78:2094-2100.
6. Hamamura K, Shiratori Y, Shiina S, Imamura M, Obi S, Sato S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000; 88:1557-1564.
7. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, et al. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2001; 16:1290-1296.
8. Dohmen K, Shigematsu H, Irie K, Ishibashi H. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin. Hepatogastroenterology 2003; 50:2072-2078.
9. Yano Y, Yamashita F, Kuwaki K, Fukumori K, Kato O, Yamamoto H, et al. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int 2006; 26:789-795.
10. Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, et al. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol 2009; 43:482-488.
11. Sakon M, Monden M, Gotoh M, Kanai T, Umeshita K, Nakano Y, et al. Relationship between pathologic prognostic factors and abnormal levels of des-gamma-carboxy prothrombin and alpha-fetoprotein in hepatocellular carcinoma. Am J Surg 1992; 163:251-256.
12. Inoue S, Nakao A, Harada A, Nonami T, Takagi H. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol 1994; 89:2222-2226.
13. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430.
14. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
15. Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 2006; 4:1528-1536.
16. Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 2008; 49:223-232.
17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC,Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
18. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Tokyo, Japan: Kanehara & Co. Ltd; 2003.
19. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751-755.
20. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38:207-215.
21. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-338.
22. Nanashima A, Taura N, Abo T, Ichikawa T, Sakamoto I, Nagayasu T, et al. Tumor marker levels before and after curative treatment as predictors of patient survival. Dig Dis Sci 2011; 56:3086-3100.
23. Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N. Clinical and molecular insights into the hepatocellular carcinoma tumor marker des-g-carboxyprothrombin. Liver Int 2011; 31:22-35.
24. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4:111-117.
25. Kitai S, Kudo M, Minami Y, Ueshima K, Chung H, Hagiwara S, et al. A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. Intervirology 2008; 51 (Suppl 1):86-94.
26. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010; 28:2889-2895.